Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 23, 2009Blood Coagulation & Fibrinolysis

Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease

View Full Paper
Ask AI
Bookmark
Share

Population

Patients with von Willebrand disease (VWD) unresponsive to desmopressin (DDAVP)

Design

Review

Authors

JBJavier BatlleUniversidade da CoruñaMFMaría Fernanda López FernándezRoyal London HospitalEFEsther Lourés FragaComplexo Hospitalario Universitario A Coruña

Discussion

Loading...

Member takes

Implication

Supports functional activity-based VWF dosing in VWD due to concentrate variability; leaves open prospective validation before practice change.

Structured PICO

P
Population
Patients with von Willebrand disease (VWD) unresponsive to desmopressin (DDAVP)
I
Intervention
Plasma-derived VWF-containing FVIII concentrates

Review highlighting the variability in VWF content among concentrates and advocating for dosing based on VWF functional activity in VWD patients.

Cite This Study

Batlle et al. (2009) studied this question.

synapsesocial.com/papers/6a9263d4397d2e5be3b891cehttps://doi.org/10.1097/mbc.0b013e3283254570
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Guidelines for the diagnosis and management of von Willebrand disease in Italy2002 · 155 citations
  2. 2von Willebrand disease: laboratory aspects of diagnosis and treatment2004 · 37 citations
  3. 3Screening for von Willebrand Disease With a New Analyzer Using High Shear Stress: A Study of 60 Cases1998 · 318 citations
  4. 4A Comparative Multi-laboratory Assessment of Three Factor VIII/von Willebrand Factor Concentrates2002 · 25 citations
  5. 5New Treatments of von Willebrand Disease: Plasma Derived von Willebrand Factor Concentrates1997 · 26 citations